EICHORPublic-registry site landscape for NCT06208124, “A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors”, a Advanced Solid Tumor (Phase 1) study sponsored by Immuneering Corporation. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06208124 (registry record) |
| Study title | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors |
| Official title | A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations |
| Sponsor | Immuneering Corporation |
| Condition(s) | Advanced Solid Tumor (Phase 1); Pancreas Adenocarcinoma; Non-small Cell Lung Cancer; Malignant Melanoma (Cutaneous) |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 5 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06208124.
Eichor generates a preliminary site-risk snapshot for NCT06208124 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Advanced Solid Tumor (Phase 1) trials
← Eichor home · All tracked trials · Advanced Solid Tumor (Phase 1) studies · Weekly briefs
